BROAD CROSS-REACTIVITY OF HIV-1 NEUTRALIZING ANTIBODY

Information

• Research Project
• 3489925

• ApplicationId

  3489925

• Core Project Number

  R43AI035427

• Full Project Number

  1R43AI035427-01

• Serial Number

  35427

• FOA Number

• Sub Project Id

• Project Start Date

  2/15/1994 - 31 years ago

• Project End Date

  8/15/1994 - 30 years ago

• Program Officer Name

• Budget Start Date

  2/15/1994 - 31 years ago

• Budget End Date

  8/15/1994 - 30 years ago

• Fiscal Year

  1994

• Support Year

  1

• Suffix

• Award Notice Date

  2/17/1994 - 31 years ago

Organizations

• TANOX, INC.

Passive immunization with broadly neutralizing antibodies is a promising approach for prevention and treatment of HIV-1 infection. We have generated an HIV-1 neutralizing human antibody which binds to the principal neutralizing determinant (PND) of the envelope glycoprotein gp12O. The antibody shows strong binding to diverse laboratory isolates as well as good neutralization ability for some of these isolates. Like other mAbs of this class, our antibody is limited in binding to a few HIV-l subtypes. We propose in this Phase I study to broaden the reactivity of the antibody through a novel combination of molecular modelling and use of the antibody phage display system. In a phase II study, promising clones with increased reactivity will be analyzed in more detail for biological activity. This analysis will also lead to further refinement of our approach.

IC Name

• Activity

  R43

• Administering IC

  AI

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  856

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  ZRG7

• Study Section Name

• Organization Name

  TANOX, INC.

• Organization Department

• Organization DUNS

• Organization City

  HOUSTON

• Organization State

  TX

• Organization Country

  UNITED STATES

• Organization Zip Code

  77025

• Organization District

  UNITED STATES